Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Morgan Stanley lowered the firm’s price target on Eli Lilly (LLY) to $1,124 from $1,146 and keeps an Overweight rating on the shares. The firm ...

KEY TAKEAWAYS The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

The Chief Executive of US pharmaceutical company Eli Lilly says it will be hard to come back from this moment.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...